Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters

alexandrossfakianakis shared this article with you from Inoreader Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters via Journal of Medical Virology Abstract Waning antibody levels against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the emergence of variants of concern (VOC) highlight the need for booster vaccinations. This is particularly important for the elderly population, who are at a higher risk of developing severe Coronavirus disease 2019 (COVID-19) disease. Whilst studies have shown increased antibody responses following booster vaccination, understanding the changes in T and B cell compartments induced by a third vaccine dose remains limited. We analysed the humoral and cellular responses in subjects who received either a homologous mRNA booster vaccine (BNT162b2+BNT162b2+BNT162b2; 'BBB') or a heterologous mRNA booster vaccine (BNT162b2+BNT162b2+mRNA-1273; 'BBM') at day 0 (pre-booster), day 7 and day 28 (post-booster). Compared to BBB, elderly individuals (≥60 years old) who received the BBM vaccination regimen display higher levels of neutralising antibodies a gainst the Wuhan and Delta strains along with a higher boost in IgG memory B cells, particularly against the Omicron variant. Circulating Th1, Th2, Th17 and Tfh responses were also increased in elderly individuals given the BBM regimen. While mRNA vaccines increase antibody, T cell and B cell responses against SARS-CoV-2 one month after receiving the third dose booster, the efficacy of the booster vaccine strategies may vary depending on age group and regimen combination. This article is protected by copyright. All rights reserved. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.